Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism , 91(3), 799-805, 2006
Rather than conducting a new meta-analysis, the authors synthesize findings from major randomized clinical trials, highlighting outcomes related to glycated hemoglobin (HbA1c), body weight reduction, major adverse cardiovascular events (MACE), and kidney function decline as reported in large cardiovascular outcomes trials (CVOTs), obesity randomized controlled trials, and early-phase clinical development studies
Int J Mol Sci (2019) 20(8):1940
US$ 27.47
US$ 29.76
US$ 29.53
US$ 27.40
